Adaptimmune Therapeutics (NASDAQ:ADAP) Downgraded by StockNews.com to Buy

StockNews.com cut shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday.

Separately, HC Wainwright cut their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $3.16.

Adaptimmune Therapeutics Stock Down 0.8 %

Shares of ADAP stock opened at $0.59 on Thursday. Adaptimmune Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.05. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.09 and a current ratio of 3.85. The business’s fifty day moving average is $0.88 and its 200-day moving average is $1.03. The stock has a market cap of $150.02 million, a PE ratio of -2.67 and a beta of 2.26.

Institutional Trading of Adaptimmune Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. raised its holdings in shares of Adaptimmune Therapeutics by 230.8% during the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 30,000 shares during the period. Fullcircle Wealth LLC purchased a new position in shares of Adaptimmune Therapeutics during the third quarter valued at $33,000. FMR LLC lifted its stake in Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after acquiring an additional 50,419 shares in the last quarter. Boulder Hill Capital Management LP acquired a new stake in Adaptimmune Therapeutics during the 1st quarter worth about $143,000. Finally, Jane Street Group LLC increased its holdings in shares of Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 98,581 shares during the period. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.